ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II

dc.contributor.authorDhakal, Sughosh
dc.contributor.authorAdvani, Ranjana
dc.contributor.authorBallas, Leslie K.
dc.contributor.authorDabaja, Bouthaina S.
dc.contributor.authorFlowers, Christopher R.
dc.contributor.authorHa, Chul S.
dc.contributor.authorHoppe, Bradford S.
dc.contributor.authorMendenhall, Nancy P.
dc.contributor.authorMetzger, Monika L.
dc.contributor.authorPlastaras, John P.
dc.contributor.authorRoberts, Kenneth B.
dc.contributor.authorShapiro, Ronald
dc.contributor.authorSmith, Sonali M.
dc.contributor.authorTerezakis, Stephanie A.
dc.contributor.authorWinkfield, Karen M.
dc.contributor.authorYounes, Anas
dc.contributor.authorConstine, Louis S.
dc.contributor.authorExpert Panel on Radiation Oncology–Lymphoma
dc.contributor.departmentRadiation Oncology, School of Medicineen_US
dc.date.accessioned2021-04-29T13:14:47Z
dc.date.available2021-04-29T13:14:47Z
dc.date.issued2016-12-01
dc.description.abstractThis topic addresses the treatment of newly diagnosed patients with favorable prognosis stage I and II Hodgkin lymphoma. In most cases, combined modality therapy (chemotherapy followed by involved site radiation therapy) constitutes the current standard of care. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the appropriate use of combined modality therapy for favorable prognosis stage I and II Hodgkin lymphoma. Increasing information about the late effects of treatment has led to attempts to decrease toxicity by using less chemotherapy (decreased duration and/or intensity or different agents) and less radiation therapy (reduced volume and/or dose) while maintaining excellent efficacy.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationDhakal, S., Advani, R., Ballas, L. K., Dabaja, B. S., Flowers, C. R., Ha, C. S., Hoppe, B. S., Mendenhall, N. P., Metzger, M. L., Plastaras, J. P., Roberts, K. B., Shapiro, R., Smith, S. M., Terezakis, S. A., Winkfield, K. M., Younes, A., Constine, L. S., & Oncology–Lymphoma, E. P. on R. (2016). ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. American Journal of Clinical Oncology, 39(6), 535–544. https://doi.org/10.1097/COC.0000000000000331en_US
dc.identifier.issn0277-3732en_US
dc.identifier.urihttps://hdl.handle.net/1805/25798
dc.publisherWolters Kluweren_US
dc.relation.isversionof10.1097/COC.0000000000000331en_US
dc.relation.journalAmerican Journal of Clinical Oncologyen_US
dc.sourcePMCen_US
dc.subjectappropriateness criteriaen_US
dc.subjectHodgkin lymphomaen_US
dc.subjectcombined modality therapyen_US
dc.titleACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and IIen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-1618685.pdf
Size:
357.32 KB
Format:
Adobe Portable Document Format
Description:
Author's manuscript
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: